Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Sequence Crossover, Drug-Drug Interaction Study to Characterize the Impact of the Cytochrome P450 3A Inhibitor Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Subjects

NCT06495944 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT06495944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06495944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Sequence Crossover, Drug-Drug Interaction Study to Characterize the Impact of the Cytochrome P450 3A Inhibitor Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Subjects
Lead sponsor
Corcept Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2024
Completion date
August 2, 2024
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adults